In my opinion, most investors hoped that the amoun
Post# of 148292
Additionally, CYDY may have hoped that a good TO would assist the company in going the combo route alone. $40 million from the TO and cash from the prostate licensing deal could potentially make that happen, but it seems unlikely with only $12 million raised.
The $12 million, plus any current cash, will hopefully get CYDY through BLA milestones, prostate test licensing and possibly TNBC interim results so that the next TO or dilution is at a higher evaluation.